953 related articles for article (PubMed ID: 9792479)
1. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
Astrup A; Lundsgaard C
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
[TBL] [Abstract][Full Text] [Related]
2. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
Van Gaal LF; Wauters MA; De Leeuw IH
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
[TBL] [Abstract][Full Text] [Related]
3. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
Astrup A
Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
[TBL] [Abstract][Full Text] [Related]
4. The effect of sibutramine intake on resting and exercise physiological responses.
Rotstein A; Inbar O; Vaisman N
Ann Nutr Metab; 2008; 52(1):17-23. PubMed ID: 18230966
[TBL] [Abstract][Full Text] [Related]
5. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
6. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
8. The effects of drugs used to treat obesity on the autonomic nervous system.
Hirsch J; Mackintosh RM; Aronne LJ
Obes Res; 2000 May; 8(3):227-33. PubMed ID: 10832765
[TBL] [Abstract][Full Text] [Related]
9. The new role of pharmacotherapy for weight reduction in obesity.
Fernstrom MH; Fernstrom JD
Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
[TBL] [Abstract][Full Text] [Related]
10. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
11. Sympathetic system activity in obesity and metabolic syndrome.
Tentolouris N; Liatis S; Katsilambros N
Ann N Y Acad Sci; 2006 Nov; 1083():129-52. PubMed ID: 17148737
[TBL] [Abstract][Full Text] [Related]
12. Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox.
Barratt R; Frost G; O'Boyle A; Millward J; Truby H
J Hum Nutr Diet; 2008 Jun; 21(3):248-55. PubMed ID: 18477180
[TBL] [Abstract][Full Text] [Related]
13. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
14. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats.
Boozer CN; Leibel RL; Love RJ; Cha MC; Aronne LJ
Metabolism; 2001 Aug; 50(8):889-93. PubMed ID: 11474475
[TBL] [Abstract][Full Text] [Related]
15. Energy balance, physical activity, and cancer risk.
Fair AM; Montgomery K
Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
[TBL] [Abstract][Full Text] [Related]
16. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
[TBL] [Abstract][Full Text] [Related]
17. Combining behavioral and pharmacological treatments for obesity.
Phelan S; Wadden TA
Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
[TBL] [Abstract][Full Text] [Related]
18. Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet.
Shick SM; Wing RR; Klem ML; McGuire MT; Hill JO; Seagle H
J Am Diet Assoc; 1998 Apr; 98(4):408-13. PubMed ID: 9550162
[TBL] [Abstract][Full Text] [Related]
19. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
